drugset / Trial / NCT00506922
Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary Objective: 1\. To determine efficacy of escalating doses of pentostatin in combination with tacrolimus and methotrexate for the prevention of acute graft-versus-host disease (GVHD) in the context of unrelated donor and one antigen mismatched related donor transplantation. Secondary Objectives: 1. To determine safety of escalating doses of pentostatin in combination with tacrolimus and methotrexate. 2. To reduce the incidence of acute GVHD following transplants with unrelated donor to 40%. 3. To document blood levels of tacrolimus when combined with pentostatin.
Timeline
- Start
- 2000-09
- Primary completion
- 2009-11
- Completion
- 2009-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pentostatin | Small molecule | 0.5 mg/m2 | Intravenous |
| Subject | Pentostatin | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Pentostatin | Small molecule | 1.5 mg/m2 | Intravenous |
| Subject | Pentostatin | Small molecule | 2 mg/m2 | Intravenous |
| Subject | Tacrolimus | Small molecule | — | Intravenous |
| Background | Methotrexate | Small molecule | 5 mg/m2 | Intravenous |